Herantis appointed a Chief Medical Officer
Translation: Original published in Finnish on 06/26/2026 at 07:20 am EEST
Herantis announced on Thursday that it had appointed Dr Juha Savola as the company's Chief Medical Officer (CMO). In our view, Savola brings very strong and relevant international experience to the company, from advancing drug development all the way to regulatory approvals. Bringing an experienced expert to the company's management supports Herantis as it prepares for the next Phase II clinical trial of the HER-096 drug candidate and negotiates with potential strategic partners.
Savola has over 25 years of experience in pharmaceutical industry leadership, clinical development, and regulatory affairs at companies such as Spark Therapeutics, Teva, and Roche. We particularly value his previous experience in leading clinical development programs for neurological diseases, such as Parkinson's disease, and in collaborating with the US (FDA) and European (EMA) regulatory agencies. Herantis aims to submit a clinical trial application for the HER-096 Phase II study by the end of 2026. At this stage, the company's key objective is a high-quality study design and achieving an international licensing agreement. We believe Savola's deep industry expertise strengthens the company's ability to successfully advance the development program.
Login required
This content is only available for logged in users
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read more on company pageKey Estimate Figures03.06.
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| growth-% | |||
| EBIT (adj.) | -6.4 | -4.1 | -6.1 |
| EBIT-% (adj.) | -63,990.0 % | -40,899.8 % | -61,199.3 % |
| EPS (adj.) | -0.27 | -0.12 | -0.18 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
